Andrew Benjamin Nixon, PhD

Professor in Medicine
Member of the Duke Cancer Institute
Campus mail 133 Jones, Research Drive, Durham, NC 27710
Phone (919) 613-7883
Email address anixon@duke.edu

Andrew Nixon, PhD, MBA (Professor of Medicine) is Director of the Phase I Biomarker Laboratory, which brings together clinical, translational and basic research to pursue the development of novel biomarkers defining mechanisms of sensitivity, resistance, and toxicity to given therapeutic drug classes, particularly anti-angiogenic agents. Additionally, the laboratory has been appointed as a Molecular Reference Laboratory for the Alliance oncology cooperative group, a national clinical trial research group sponsored by the National Cancer Institute. The laboratory has quality control procedures in place to address many of the issues involved in clinical trial research including determination of sample quantity, sample integrity, and sample heterogeneity. We have spent considerable time developing robust assays that utilize limited amounts of specimen while providing high quality data. Multiplex ELISA and gene expression arrays are used to analyze serially collected blood and paraffin samples archived from cancer patient clinical trials. This work has the potential to improve the efficacy and toxicity of current therapies and to guide the development of the next generation of anti-angiogenesis therapies for cancer and other diseases.

Education and Training

  • M.B.A., Duke University, 2007
  • Ph.D., Wake Forest University, 1997

Grants

Publications

Guercio, Brendan John, Alan P. Venook, Sui Zhang, Fang-Shu Ou, Donna Niedzwiecki, Heinz-Josef Lenz, Federico Innocenti, et al. “Associations of insulin-like growth factor binding proteins and adiponectin with disease progression and mortality in metastatic colorectal cancer: Results from CALGB/SWOG 80405 (Alliance).” In Journal of Clinical Oncology, 37:3035–3035. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.15_suppl.3035.

Full Text

Kim, Dae Won, Hanna Kelly Sanoff, Andrew Stewart Poklepovic, Fatima Tariq, Andrew B. Nixon, Yingmiao Liu, and Richard D. Kim. “Final analysis of phase II trial of regorafenib (REG) in refractory advanced biliary cancers (BC).” In Journal of Clinical Oncology, 37:4083–4083. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.15_suppl.4083.

Full Text

Park, Haeseong, Nikolaos Trikalinos, Aravind Sanjeevaiah, Katrina Pedersen, Nusayba Ali Bagegni, Andrew B. Nixon, Jesse Huffman, et al. “Ramucirumab and irinotecan in patients with previously treated gastroesophageal adenocarcinoma.” In Journal of Clinical Oncology, 37:TPS4150–TPS4150. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.15_suppl.tps4150.

Full Text

Hsi, Eric D., Hongli Li, Andrew B. Nixon, Heiko Schöder, Nancy L. Bartlett, Michael LeBlanc, Sonali Smith, et al. “Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study.” Blood 133, no. 16 (April 18, 2019): 1762–65. https://doi.org/10.1182/blood-2018-08-870915.

PMID
30723079
Full Text

Liu, Yingmiao, Kirsten Burdett, Mark D. Starr, J Chris Brady, Ace Joseph Hatch, Anastasia Ivanova, Dominic T. Moore, et al. “Blood-based biomarkers in metastatic colorectal cancer patients treated with FOLFIRI plus regorafenib or placebo: Results from LCCC1029.” In Journal of Clinical Oncology, 37:587–587. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.4_suppl.587.

Full Text

Hatch, Ace Joseph, Fang-Shu Ou, Tyler Zemla, Mark D. Starr, John C. Brady, Yingmiao Liu, Federico Innocenti, et al. “On-treatment changes of plasma protein biomarkers in CALGB/SWOG 80405 (Alliance).” In Journal of Clinical Oncology, 37:588–588. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.4_suppl.588.

Full Text

Choueiri, Toni K., M Dror Michaelson, Edwin M. Posadas, Guru P. Sonpavde, David F. McDermott, Andrew B. Nixon, Yingmiao Liu, et al. “An Open Label Phase Ib Dose Escalation Study of TRC105 (Anti-Endoglin Antibody) with Axitinib in Patients with Metastatic Renal Cell Carcinoma.” Oncologist 24, no. 2 (February 2019): 202–10. https://doi.org/10.1634/theoncologist.2018-0299.

PMID
30190302
Full Text

Innocenti, Federico, Chen Jiang, Alexander B. Sibley, Amy S. Etheridge, Ace J. Hatch, Stefanie Denning, Donna Niedzwiecki, et al. “Genetic variation determines VEGF-A plasma levels in cancer patients.” Sci Rep 8, no. 1 (November 5, 2018): 16332. https://doi.org/10.1038/s41598-018-34506-4.

PMID
30397360
Full Text

Innocenti, F., C. Jiang, A. B. Sibley, S. Denning, A. S. Etheridge, D. Watson, D. Niedzwiecki, et al. “A genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients.” In Ann Oncol, 29 Suppl 8:viii661–62, 2018. https://doi.org/10.1093/annonc/mdy303.038.

PMID
32137805
Full Text

Das, R. K., L. Furchtgott, F. -. S. Ou, D. Swanson, B. Hayete, B. Harms, D. Cunha, et al. “Causal modeling of CALGB/SWOG 80405 (Alliance) identifies primary (1°) side-related angiogenic drivers of metastatic colorectal cancer (mCRC).” In Ann Oncol, 29 Suppl 8:viii152, 2018. https://doi.org/10.1093/annonc/mdy281.006.

PMID
32136255
Full Text

Pages